The biotech firm closed an oversubscribed Series C funding round, proceeds from which it will use to advance ATSN-201 and its ...

The commission approved the new formulation in first- and second-line NSCLC settings, in which intravenous Rybrevant is already available.

The firm will evaluate CVHNLC in combination with Keytruda as a first-line and first-line maintenance treatment in NSCLC.

The combined company will clinically advance Epsilogen's MOv18 IgE antibody in ovarian cancer and TigaTx's anti-EGFR IgA antibody.

The firm plans to use improvement in left ventricular mass index and increased frataxin protein expression after LX2006 treatment as co-primary endpoints.

Researchers urged hospitals to set up processes for updating pharmacogenomic results, but it's unclear how frequently that ...

The benefits of early TAVR for patients with asymptomatic, severe aortic stenosis are consistent regardless of NT-proBNP or ...

Patients at risk for heart disease experienced significant reductions in apolipoprotein B and LDL cholesterol levels on ...

Researchers shared data at ACC from BioCardia's initial Phase III cell therapy trial, which the firm stopped enrolling based ...

The organizations launched the clinical trial to assess clinical utility of whole-genome sequencing in cardiovascular disease ...

Eli Lilly's next Phase III trial is assessing whether lepodisiran can not only reduce levels of lipoprotein(a) but also ...

The firm said the clinical trial pause is temporary as an independent data monitoring committee finalizes its analysis for submission to regulators.